- Drug Pipelines
- June 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- April 2024
- 65 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2025
- 250 Pages
Global
From €4752EUR$4,999USD£3,992GBP
- Report
- November 2024
- 188 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 250 Pages
Global
From €4752EUR$4,999USD£3,992GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- February 2025
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2024
- 186 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 116 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- July 2024
- 154 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- March 2025
- 210 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- November 2024
- 261 Pages
Global
From €4278EUR$4,500USD£3,594GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more